Clinical TrialAug 11, 2026, 07:27 AM
Tango Therapeutics Vopimetostat 92% ORR in Pancreatic Cancer; Plans Phase 3
AI Summary
Tango Therapeutics reported positive Phase 1/2 data for vopimetostat in combination with daraxonrasib, achieving a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted, RAS-mutant pancreatic cancer. The company plans to advance this combination into Phase 3 development and will present data at the 2026 ESMO Congress. For Q2 2026, Tango reported a net loss of $55.3 million, or $0.37 per share, and held $1.0 billion in cash. Additionally, Fatma Ocak was appointed Chief Commercialization Officer and Robert Azelby became Chairman of the Board.
Key Highlights
- Vopimetostat in combination with daraxonrasib achieved 92% objective response rate in pancreatic cancer.
- Vopimetostat combination showed 90% six-month progression-free survival in pancreatic cancer.
- Company plans to advance vopimetostat combination into Phase 3 development for pancreatic cancer.
- Fatma Ocak appointed Chief Commercialization Officer, effective August 17, 2026.
- Robert Azelby appointed Chairman of the Board of Directors on August 6, 2026.
- Cash, cash equivalents, and marketable securities totaled $1.0 billion as of June 30, 2026.
- Q2 2026 net loss was $55.3 million, or $0.37 per share.
- Q2 2026 R&D expenses increased to $37.2 million from $32.8 million year-over-year.
Price Impact
More from TNGX